Status:

WITHDRAWN

Treatment of Depersonalization Disorder With Repetitive Transcranial Magnetic Stimulation (rTMS)

Lead Sponsor:

New York State Psychiatric Institute

Collaborating Sponsors:

City University of New York, School of Public Health

Conditions:

Depersonalization Disorder

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

This is a randomized controlled trial (RCT) on the efficacy of repetitive Transcranial Magnetic Stimulation (rTMS) in the treatment of Depersonalization Disorder (DPD). TMS applies a magnetic field to...

Detailed Description

This study is a research trial of an outpatient, non-medication, non-invasive investigational treatment called Transcranial Magnetic Stimulation (TMS). TMS is a noninvasive tool for the study of the h...

Eligibility Criteria

Inclusion

  • Male or female outpatients, 18 to 70 years of age.
  • Primary diagnosis of Depersonalization Disorder.
  • Duration of the index episode of at least a year.
  • Patients currently on DPD medication must be at the same stable dose(s) at least 2 months and be to continue at the same dose(s) through the duration of the study.
  • Patients must continue to be under the care of their treating psychiatrist who will be writing prescriptions for concomitant medications through the duration of the study.
  • Capable and willing to provide informed consent

Exclusion

  • Individuals diagnosed with current Major Depressive Disorder or Panic Disorder.
  • Individuals diagnosed with the following conditions: Bipolar Disorder (lifetime), any Psychotic Disorder (lifetime), History of substance abuse or dependence within the past yea (except nicotine and caffeine).
  • Individuals with a neurological disorder including, but not limited to: brain lesion; history of seizures; history of cerebrovascular accident; history of stroke; TIA, cerebral aneurysm, Dementia; Parkinson's Disease; Huntington's chorea; Multiple Sclerosis.
  • Increased risk of seizure for any reason, including prior head trauma with loss of consciousness for 5 minutes or more
  • Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease.
  • Intracranial implants (e.g. aneurysms clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed.
  • History of treatment with rTMS therapy for any disorder.
  • If participating in psychotherapy, must have been in stable treatment for at least three months prior to entry into the study, with no anticipation of change in frequency of therapeutic sessions, or the therapeutic focus over the duration of the rTMS trial.
  • Known or suspected pregnancy.
  • Women who are breast-feeding

Key Trial Info

Start Date :

October 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2016

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT02256085

Start Date

October 1 2013

End Date

December 1 2016

Last Update

March 24 2017

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Sophie Davis School of Biomedical Education, City University of New York (CUNY)

New York, New York, United States, 10031

2

New York State Psychiatric Institute, Experimental Therapeutics

New York, New York, United States, 10032